Dextera Surgical Inc

Dextera Surgical — IPO Roadshow (April 2017)

27 slides from Dextera Surgical's IPO roadshow presentation, Apr 21, 2017

  1. Slide 1: Dextera Surgical Investor Presentation April 2017

    Dextera Surgical Investor Presentation April 2017 NASDAQ: DXTR

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement 2 The following material contains forward - looking statements, including statements regarding Dextera Surgical’s future, business strategy, product development and plans and objectives of management for future operations. The words “may,” “continue,” “potential,” “estimate

  3. Slide 3: Investment Overview

    Investment Overview • Two proprietary medical technology platforms advancing minimally invasive surgery • MicroCutter – Smallest diameter articulating surgical stapler – $2 billion total WW surgical stapling market – 66 issued patents; CE Mark and 510(k) cleared – Intuitive Surgical license (paid $1

  4. Slide 4: Growing Demand for Minimally Invasive Surgery

    Growing Demand for Minimally Invasive Surgery Less pain, faster recovery & shorter hospital stays driving provider’s interest and patient demand for less invasive surgery Early diagnosis and detection leading patients and surgeons to look for less invasive approaches to treat smaller lesions Shift f

  5. Slide 5: Minimally Invasive Surgery Technology Platforms

    Minimally Invasive Surgery Technology Platforms Dextera developed and commercialized two technology platforms addressing the need for less invasive surgery Only FDA - cleared products for BOTH proximal & distal automated anastomoses of vessels in CABG procedures The first and only 5mm stapler with 8

  6. Slide 6: Strategic Partners: Intuitive Surgical Co-development Agreement

    Strategic Partners: Intuitive Surgical Co - development Agreement 6 NASDAQ:ISRG $27.4 billion market cap $2.7 billion in sales (FY’16) Intuitive Surgical (NASDAQ:ISRG) first licensed DXTR’s technology in August 2010 • Has received over $14MM from Intuitive Surgical for exclusive robotic application

  7. Slide 7: Strategic Partners: B. Braun/Aesculap Strategic Partnership Agreement

    Strategic Partners: B. Braun/Aesculap Strategic Partnership Agreement 7 Euro 6.4 Billion in sales (FY16) • Launched MicroCutter in Spain with B. Braun in Q1 CY17 • Preliminary discussions in progress for a strategic partnership, including: – Expansion of current distribution agreement for MicroCutte

  8. Slide 8: Dextera has developed the world's smallest profile articulating surgical stapling device

    … developed the world’s smallest profile articulating surgical stapling device to advance minimally invasive surgery so surgeons can improve patient outcomes. 8 Dextera has… 80º articulation • Up to 78% greater articulation • Increased angle of reach and unprecedented access to the surgical site 5mm

  9. Slide 9: Size Matters for Minimally Invasive Surgery

    Size Matters for Minimally Invasive Surgery 9 5mm 8mm 10 or 12mm 15mm Grasper Camera Clip Applier Sealing Device Current Staplers Current market Intuitive

  10. Slide 10: Key Competitive Advantages

    Smallest Surface Area Widest Articulation Broadest Reach Up to 51% smaller surface area At least 33% more reach Up to 78% greater articulation Key Competitive Advantages 10 Enabling MIS procedure approaches that are “not possible with either the JustRight stapler or conventional staplers” (Pediatric

  11. Slide 11: Conventional Stapler Dimensions

    Conventional Stapler Dimensions Driver Staple Tissue Gap Channel Anvil 11 Classic B - Staple Tine Length = Form Factor Current Endostaplers Green Anvil = 4mm Tissue Gap = 1.5mm Staple = 4.3mm Driver = 1.5mm Channel = 1.5mm 12.4mm

  12. Slide 12: Unique Approach & Robust Intellectual Property

    Unique Approach & Robust Intellectual Property Driverless deployment from staples - on - a - strip Staples shaped like a suture needle Staple deployed by wedge (no driver) making direct contact with staple Accurate motion frangibly separates staple from strip PATENTS U.S. 55 Issued 30 Pending Foreig

  13. Slide 13: Market Opportunity

    Market Opportunity 13 $2B global market for minimally invasive surgical stapling products growing at 8% CAGR through 2024 Source: IMS Data, Company Estimates & Grandview Research 2016

  14. Slide 14: Large Addressable Market

    Large Addressable Market 14 Total U.S. Surgeries Estimated 2,500,000 Procedures Annually Thoracic: 147k $1,500/procedure TAM: $220M Lobectomy/Segmentectomy: 95k Wedge Resection: 39k Esophagectomy: 7k Pediatric: 53k $1,400/procedure TAM: $74M Thoracic to Colorectal: 53k Parenchymal: 82k $1,050/proced

  15. Slide 15: U.S. Endo Stapling Market

    15 Source: IMS Data & Company Estimates U.S. Endo Stapling Market Staple Height U.S. ($MM) Mix Thin/Vascular $374 42% Medium $333 37% Thick $187 21% Total $894 100% White & blue sizes for cartridge reloads cover 79% of the US market 15

  16. Slide 16: Commercialization Strategy

    16 Thoracic KOLs in Leading Hospitals Drive Deeper Penetration in Existing Accounts Drive Growth in Target Geographies Innovators 150 cases/yr Early Adopters 100 cases/yr Fast Followers Laggards Commercialization Strategy 1 Focused approach for hospital entry 2 3 Expanding usage to Pediatric & Solid

  17. Slide 17: MATCH Trial to Document Excellent Clinical Performance

    MATCH Trial to Document Excellent Clinical Performance • Study evaluating hemostasis and procedure enabling aspects of MicroCutter 5/80 – Enrolled 43 of 60+ patients in world leading thoracic centers • Covers all procedure approaches to lobectomy – Robotic, uniportal, microlobectomy, anterior, poste

  18. Slide 18: Dextera commercialized the only FDA cleared products for proximal & distal automated anastomoses

    … commercialized the only FDA cleared products for BOTH proximal & distal automated anastomoses of vessels in CABG Procedures 18 Dextera has… C - Port xA ® Distal Anastomosis System • Enables automated, reliable, reproducible and compliant connections of blood vessels during CABG (coronary artery by

  19. Slide 19: Strong Clinical Support for CABG Procedures

    • Procedure stability driven by MIS technologies • Reduced incidence of post - op stroke • Reduce length - of - stay • Eliminate sternal access, wound infections • Maximize use of arterial grafts for improved patency rates Strong Clinical Support for CABG Procedures 19 700,000 Annual CABG Procedures

  20. Slide 20: FY17 & FY18 Milestones

    FY17 & FY18 Milestones 20 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 Execute strategic partnership with B. Braun Supply chain optimization & establish product capacity of 120 MCs/week Enrollment completed for MATCH Registry Expand MC indication to include liver in US Expand product pipeline Drive clinical adopti

  21. Slide 21: Financial Highlights

    $55k $282k $516k $700k - $800k Thousands 21 Financial Highlights FY16 Sales Cardiac products $2.2M MicroCutter products 0.4M License & royalty 1.5M Total Sales $4.1M MicroCutter FY17 Sales Forecast $1.5 - $1.6M

  22. Slide 22: Balance Sheet & Cap Structure

    Balance Sheet & Cap Structure Balance Sheet as of 12/31/16 Cash, Cash Equivalents & Investments $5.8M Total Assets $8.9M Current & Other Liabilities $4.5M LT Note Payable $4.0M Shareholders’ Equity $0.4M Shares Outstanding as of 12/31/16 Common Shares (Pre - offering) 8.9M Option & RSUs 1.6M Preferr

  23. Slide 23: New Management Team: Proven Med-Tech Leaders

    New Management Team: Proven Med - Tech Leaders Julian Nikolchev President, CEO & Director ( Oct. 2015 ) 23 • Founder, CEO & CTO of Pivot Medical, acquired by Stryker in 2014, now a leading product line for Stryker Sports Medicine Company • Served as a venture partner at Frazier Healthcare Ventures,

  24. Slide 24: New Management Team: Proven Med-Tech Leaders

    New Management Team: Proven Med - Tech Leaders Tom Palermo Chief Operating Officer ( Nov. 2015 ) • CEO, UlceRx Medical • President & CEO, ReVascular Therapeutics • VP, Operations & Engineering, Ensure Medical • New Hampshire College, BS Liam Burns VP, Sales & Marketing ( Jan. 2014 ) • VP Marketing,

  25. Slide 25: Summary: Dextera At Inflection Point

    Summary: Dextera At Inflection Point 25 • New management team with proven commercial track record • MicroCutter redesign completed, demonstrated improved performance and encouraging clinical feedback from target KOLs • Intuitive Surgical agreement validates and expands MicroCutter platform • Potenti

  26. Slide 26: Breakthrough technologies to advance minimally invasive surgery

    Breakthrough technologies to advance minimally invasive surgery

  27. Slide 27: Board of Directors: Strong Team of Med-Tech Leaders

    Board of Directors: Strong Team of Med - Tech Leaders Mike Bates Chairman • Moximed, consulting CFO, ‘08 - ’15 • St. Francis Medical, CFO, ‘05 - ’07 • Silicon Genetics, CFO, ‘00 - ’04 • Collagen Aesthetics, CFO, ‘99 - ’00 Greg Casciaro Director • Cardiac Dimensions, President & CEO, ‘15 - present •

Dextera Surgical — IPO Roadshow (April 2017) on 6ix